reviral company logo

ReViral – Fusion Inhibitors for RSV

ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.

  • Respiratory Syncytial Virus (RSV) represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity.
  • ReViral is developing a fusion inhibitor of RSV which is a highly potent, novel small molecule
  • Currently in phase 1 clinical trail
  • Reviral's pipeline includes non-fusion inhibitors of RSV replication

Upcoming Events

January 9–11, 2017
ReViral's CEO Eddy Littler will be presenting at the 9th Annual Biotech Showcase
San Francisco, CA 94102 USA

9-13 January 2017
The J.P. Morgan 35th Annual Healthcare Conference
San Francisco, CA, USA

20-22 March 2017
BIO Europe Spring meeting

Barcelona, Spain



Latest News
Oct 31, 2016
ReViral initiates Phase 1 clinical trial of potent oral inhibitor against Respiratory Syncytial Virus
London, UK, 31 st October 2016 - ReViral, an antiviral drug...
Oct 3, 2016
ReViral Announces Appointment of New Chief Executive Officer
London, UK, 3rd October 2016 / ReViral Ltd, a biotechnology company, aiming...